Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT02259621 |
| Title | Neoadjuvant Anti-PD-1, Nivolumab in Resectable NSCLC |
| Acronym | NA_00092076 |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Sidney Kimmel Comprehensive Cancer Center |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA | CAN |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Johns Hopkins at Bayview Medical Center | Baltimore | Maryland | 21224 | United States | Details | |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Baltimore | Maryland | 21287 | United States | Details | |
| Memorial Sloan Kettering | New York | New York | 10065 | United States | Details | |
| Swedish Cancer Insitute | Edmonds | Washington | 98026 | United States | Details | |
| Johnathan Spicer | Montréal | Quebec | H4 3J1 | Canada | Details |